Larimar Therapeutics, Inc.

LRMR · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.1%

Institutions93.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	–	$0	$0	$0	$0	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$172.50M	-$90.89M	-$36.53M	-$50.47M	-$42.80M	-$45.65M	-$61.12M	-$53.00M	-$58.23M	-$73.81M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$165.67M	-$80.60M	-$35.40M	-$50.60M	-$42.48M	-$45.41M	-$61.37M	-$52.03M	-$57.88M	-$74.29M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.46	$-1.00	$-1.00	$-2.95	$-3.57	$-1.00	$-1.00	$-1.00	$-2.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.46	$-1.00	$-1.00	$-2.95	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$85.41M	$33.22M	$26.82M	$70.10M	$68.15M	$27.21M	$49.33M	$40.78M	$32.35M	$35.59M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$145.84M	$200.22M	$126.41M	$78.67M	–	$80.73M	$121.76M	$105.51M	$131.62M	$189.11M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	$7.27M	$5.46M	–	$3.59M	$2.94M
Everything the company owes — debt, unpaid bills, and other obligations.	$67.76M	$28.41M	$15.50M	$14.25M	–	$27.11M	$28.49M	$27.29M	$9.89M	$20.00M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$78.08M	$171.81M	$110.90M	$64.41M	–	$53.62M	$93.27M	$78.22M	$121.73M	$169.11M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$113.20M	-$70.80M	-$27.57M	-$42.10M	-$42.20M	-$40.78M	-$51.49M	-$43.78M	-$51.98M	-$59.55M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$91000	$515000	$100000	$333000	$62000	$764000	$108000	$55000	$660000	$595000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$113.29M	-$71.31M	-$27.67M	-$42.44M	-$42.26M	-$41.55M	-$51.59M	-$43.84M	-$52.63M	-$60.15M

	You	Peer avg
Revenue Growth	–	+8.9%
ROE	-139.6%	-43.9%

Larimar Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison